¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"chief cell type i glomus cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • fluorescence activated cell sorter
    Çü±¤Ç¥Áö¼¼Æ÷ºÐ·ù±â
  • foam cell
    °Åǰ¼¼Æ÷
  • follicle cell
    1. ¼ÒÆ÷¼¼Æ÷ 2. ³­Æ÷¼¼Æ÷
  • follicular cell
    1. ¼ÒÆ÷¼¼Æ÷ 2. ³­Æ÷¼¼Æ÷
  • foreign body giant cell
    À̹°°Å´ë¼¼Æ÷
  • fusiform cell
    ¹æÃß¼¼Æ÷
  • G cell
    G¼¼Æ÷
  • Gaucher cell
    °í½¦¼¼Æ÷
  • germ cell
    Á¾ÀÚ¼¼Æ÷, »ý½Ä¼¼Æ÷, ¹è¼¼Æ÷
  • germinal cell
    Á¾ÀÚ¼¼Æ÷
  • ghost cell
    À¯·É¼¼Æ÷
  • ghost cell glaucoma
    ºó¼¼Æ÷³ì³»Àå, À¯·É¼¼Æ÷³ì³»Àå
  • giant cell
    °Å´ë¼¼Æ÷
  • giant cell carcinoma
    °Å´ë¼¼Æ÷¾ÏÁ¾
  • giant cell epulis
    °Å´ë¼¼Æ÷Ä¡ÀºÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • erythroid cell
    (¢¡red blood cell) ÀûÇ÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý, »ç°ñºÀ¼Ò
  • ethmoidal air cell
    ¹úÁý»À¹úÁý, »ç°ñ¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • fat-storing cell
    Áö¹æÀúÀå¼¼Æ÷
  • flagellated cell
    Æí¸ð¼¼Æ÷
  • foam cell
    °Åǰ¼¼Æ÷
  • follicle cell
    ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
  • follicular cell
    (¢¡follicle cell) ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
  • foreign body giant cell
    À̹°°Å´ë¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • anoxic cell
    ¹«»ê¼Ò¼¼Æ÷
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • apex of cell
    ¼¼Æ÷²À´ë±â
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arteritis,giant cell of aorta
    ´ëµ¿¸Æ(ÓÞÔÑØæ)ÀÇ °Å¼¼Æ÷¼º(ËÝá¬øààõ)
  • free cell
    ÀÚÀ¯¼¼Æ÷(í»ë¦á¬øà).
  • functional cell
    ±â´É¼¼Æ÷(ѦÒöá¬øà).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • thinking type
    »ç°íÇü(ÞÖÍÅúþ).
  • triaxone type
    »ïÃàÇü(ß²õîúþ).
  • tuberculoid (type) leprosy
    À¯°áÇÙ³ª(׾̿ú·ÑÛ), °áÇپ糪(Ì¿ú·åÆÑÛ).
  • tuberculoid (type) leprosy
    À¯°áÇÙ³ª(׾̿ú·ÑÛ), °áÇپ糪(Ì¿ú·åÆ )
  • type A behavior
    AÇü Çൿ(ú¼ÔÑ).
  • type A encephalitis
    ±â¸é¼º ³ú¿°(ÐîØùàõÒàæú).
  • type A personality theory
    AÇü ÀΰÝÀÌ·Ð(ìÑÌ«ìµÖå).
  • type A(B) personality
  • type B encephalitis =Japanese e.
    BÇü ³ú¿°.
  • type B encephalitis =Japanese e.
    BÇü ÀϺ»³ú¿°.
  • type I << antibody excess >>
    IÇü << Ç×ü°úÀ× >>
  • type I human t lymphotropic virus
    IÇü ÀÎ t ¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type I hyperlipoproteinemia
    I Çü °úÁö´Ü¹éÇ÷Áõ
  • type II glycogen storage disease
    ´ç¿øÀúÀ庴IIÇü(ÓØê«îÍíúÜ»ì£úþ).
  • type II human T lymphotropic virus
    II Çü ÀÎ T ¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • Spinous cell
    °¡½Ã¼¼Æ÷
    [¿¾ ¿ë¾î] À¯±Ø¼¼Æ÷
  • Dendriform cell
    ³ª¹µ°¡Áö¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁö»ó¼¼Æ÷
  • Endocrine cell
    ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ºÐºñ¼¼Æ÷
  • Colliculiform cell
    µÐ´ö¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Ò±¸¼¼Æ÷
  • Microvillous cell
    ¹Ì¼¼À¶¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼À¶¸ð¼¼Æ÷
  • Smooth muscle cell
    ¹Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ÆòȰ±Ù±Ù¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸í¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸íÁÖ¼¼Æ÷
  • Fusiform cell
    ¹æÃß¼¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃ߻󼼯÷
  • Supporting cell
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Cell of reticulum
    ¹úÁýÀ§Ä­
    [¿¾ ¿ë¾î] ¼¼¸Á¼¼Æ÷
  • Kupffer`s cell
    º°Å«Æ÷½Ä¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼¸Á³»ÇǼ¼Æ÷
  • Mitotic cell
    ºÐ¿­±â¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐ¿­±â¼¼Æ÷
  • Intermitotic cell
    ºÐ¿­»çÀ̱⼼Æ÷
    [¿¾ ¿ë¾î] °£±â¼¼Æ÷
  • Epitheloid muscle cell
    »óÇǼº±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǾç±Ù¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
CNF chronic nodular fibrositis; congenital nephrotic syndrome of the Finnish [type]
CPK-BB creatine phosphokinase, brain-type
CR1 complement receptor type 1
CRPS complex regional pain syndrome [type I and II]
CSB contaminated small bowel; craniosynostosis, Boston type
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
BPV1 Bovine Papilloma Virus type 1
BAV-3 Bovine adenovirus type 3
BPV-4 Bovine papillomavirus type 4
bPIV3 Bovine parainfluenza virus type 3
CNP C type natriuretic peptide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cornified epithelial cell
    °¢È­ »óÇÇ ¼¼Æ÷
  • cortical cell
    ÇÇÁú ¼¼Æ÷
  • crystal cell
    °áÁ¤ ¼¼Æ÷
    ³»ºÎ¿¡ °¢Á¾ °áÁ¤À» ÇÔÀ¯ÇÏ´Â ¼¼Æ÷. ºÐºñ ¼¼Æ÷ÀÇ ÀÏÁ¾À¸·Î, º¸Åë ÁÖÀ§ÀÇ ¼¼Æ÷¿Í ¸ð¾çÀÌ ¾à°£ ´Ù¸£´Ù. Á¤¹æÁ¤°è ¶Ç´Â ´Ü»çÁ¤°è·Î µÈ Å« ¿Á»ì»ê Ä®½· °áÁ¤À» º£°í´Ï¾Æ¼Ó µî ½Ä¹°Á¶Á÷ ³»¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Ù. ¶§·Î´Â ¼ÒÇüÀÇ °áÁ¤ÀÌ ´Ù¼ö ±ºÁýÇÏ¿© °áÁ¤»ç°¡ µÇ°Å³ª ħ»ó °áÁ¤ÀÌ ´Ù¼ö ÆòÇàÀ¸·Î ¹è¿­µÇ¾î °áÁ¤ ¼ÓÀÌ µÈ´Ù
  • cutaneous B cell lymphoma
    ÇǺΠB ¼¼Æ÷ ¸²ÇÁÁ¾
  • cylindrical cell
    ¿øÁÖÇü ¼¼Æ÷, ¿øÁÖ»ó ¼¼Æ÷
  • daughter cell
    µþ ¼¼Æ÷, ³¶ ¼¼Æ÷
    1. ¸ð¼¼Æ÷°¡ ºÐ¿­ÇÏ¿© »ý±â´Â ¼¼Æ÷. 2. ¼¼Æ÷ ºÐ¿­ÀÇ °á°ú·Î »ý±ä 2°³ÀÇ »õ·Î¿î ¼¼Æ÷. ºÐ¿­ ÀüÀÇ ¸ð¼¼Æ÷¿¡ ´ëÇØ¼­ µþ ¼¼Æ÷¶ó°í ÇÏ¸ç ³¶ ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. µþ ¼¼Æ÷ÀÇ ÇÙÀº 2°³°¡ ¼­·Î ³»¿ëÀÌ °°À¸¸ç, ¶Ç ¸ð¼¼Æ÷ÀÇ ÇÙ°úµµ ¶È°°Àºµ¥ ¼¼Æ÷ÁúÀº ¾à°£ ´Ù¸£´Ù. °¨¼öºÐ¿­ÀÇ Á¦1ºÐ¿­¿¡ ÀÇÇÏ¿© »ý±â´Â 2°³ÀÇ µþ¼¼Æ÷ÀÇ ¿°»öü ¼ö´Â ¸ð¼¼Æ÷ÀÇ ¹Ý¼ö·Î µÇ¾î ÀÖ´Â °ÍÀÌ º¸ÅëÀÌ´Ù.
  • Deiters cell
    ´ÙÀÌÅ׸£½º ¼¼Æ÷
    ³»ÀÌÀÇ ´ÞÆØÀ̰ü ³»ÀÇ ±âÀú¸· À§¿¡ ÀÖ´Â ÄÚ¸£Æ¼±â¸¦ ±¸¼ºÇÏ´Â ÀÏÁ¾ÀÇ ¼¼Æ÷. Á÷Á¢ ¼Ò¸® °¨°¢À» ¹Þ´Â ¿ÜÀ¯¸ð¼¼Æ÷ °£±ØÀ» ä¿ì°í ÀÖ´Â ÁöÁö¼¼Æ÷.
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
  • diploid cell
    2¹èü ¼¼Æ÷
    Á¤»óÀÇ 2¹è¼ºÀÇ ¿°»öü, ¶Ç´Â 2°³ÀÇ ÇÙÀ» °¡Áø ¼¼Æ÷. Á¤»óÀÎ Á¶Á÷ ¾È¿¡¼­´Â ¼öÁ¤¶õÀ̳ª ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ º¼ ¼ö ÀÖ´Ù. ÀΰøÀûÀ¸·Î´Â HVJ³ª NDA µîÀÇ ¹ÙÀÌ·¯½º³ª
  • direct cell division
    Á÷Á¢ ¼¼Æ÷ ºÐ¿­
  • disintegrated cell
    ºØ±« ¼¼Æ÷
  • dorsal horn cell
    Èİ¢ ¼¼Æ÷, ¹è°¢ ¼¼Æ÷
  • dorsal horn pain transmission cell
    ¹è°¢ ÅëÁõ Àü´Þ ¼¼Æ÷, ¹è°¢ µ¿Åë Àü´Þ ¼¼Æ÷
  • ductal cell
    µµ°ü ¼¼Æ÷
  • ductule cell
    ¼Ò°ü ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
type IV acrocephalosyndactyly Acrocephalosyndactyly with pointed nose, hypertelorism, cleft palate, congenital heart disease and pseudohermaphroditism; contractures of elbows and knees; soft tissue syndactyly, absent first metatarsal and great toe. Autosomal recessive.
(05 Mar 2000)
type IV collagen A less distinctly fibrillar form of collagen characteristic of basement membranes.
(05 Mar 2000)
type IV familial hyperlipoproteinaemia Plasma levels of VLDL, pre-beta-lipoproteins and triglycerides are increased on a normal diet, but beta-lipoproteins, cholesterol, and phospholipids are normal; hypertriglyceridemia is induced by a high carbohydrate diet; may be accompanied by abnormal glucose tolerance and susceptibility to ischemic heart disease; probably autosomal recessive inheritance.
Synonym: carbohydrate-induced hyperlipaemia, familial hyperprebetalipoproteinaemia, familial hypertriglyceridemia.
(05 Mar 2000)
type IV prepilin peptidase <enzyme> Product of the pulc-o pullulanase secretion gene operon; involved in processing prepilin signal peptide; may also function as an n-methyltransferase
Registry number: EC 3.4.99.-
Synonym: pulo protein, pulo gene product, pulo peptidase
(26 Jun 1999)
type locality <zoology> The geographical location of the occurrence of the population from which the type specimen was taken. Population occurring at type locality = topotypical population. Specimens collected at type locality = topotypes.
(09 Jan 1998)
type material <zoology> A collective term for all type specimens. Zoologists should ensure that such material is transferred as quickly as possible to public institutions where their safety is guaranteed and they are accessible to other workers.
(09 Jan 1998)
type series <zoology> The series of specimens which either constitutes the name-bearing type of a nominal species or subspecies or from which the name-bearing type has been or may be designated.
(09 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
ÅëÇÕ°Ë»ö ¿Ï·á